E-Selectin and markers of HIV disease severity, inflammation and coagulation in HIV-infected treatment-naïve individuals|
Hoffman, Madelein; Ipp, Hayley; Phatlhane, Dineo V; Erasmus, Rajiv T & Zemlin, Annalise E
Background: E-selectin has been shown to play a role in atherosclerosis and to be increased in HIV-infected individuals due to
chronic immune activation. There is a paucity of studies on E-selectin in HIV-infected treatment-naïve individuals.
Objectives: This study aimed to determine whether E-selectin levels were increased in HIV-infected treatment-naïve individuals
and whether these correlated with markers of disease severity, inflammation and coagulation to determine if this population is
at risk for cardiovascular disease (CVD).
Methods: E-selectin levels were determined in 114 HIV-infected treatment-naive and 66 HIV-negative individuals, compared
between groups and correlated with markers of disease severity, inflammation and coagulation.
Results: There were statistically significant differences (p<0.01) in levels of WCC, CD4+ count, %CD38/8, albumin, IgG,
hsCRP and D-dimer between groups and no statistically significant differences in E-selectin (p=0.84) and fibrinogen (p=0.65)
levels. E-selectin correlated with age (p=0.02) and gender (p=0.01).
Conclusion: E-selectin was a poor marker in this setting. There was no correlation with any of the markers of disease severity,
inflammation and coagulation. E-selectin is most likely raised in an acute inflammatory setting, rather than chronic stage of
HIV-infection. We recommend that other markers be utilized to identify patients at increased risk of CVD; as these were significantly
increased untreated in individuals.
E-selectin; inflammation and coagulation in HIV-infected treatment-naïve individuals.